Response to osimertinib plus trametinib in a heavily treated epidermal growth factor receptor (EGFR)-positive NSCLC harboring a rare, acquired rapidly accelerated fibrosarcoma B-type (BRAF) p.D594N mutation: a case report.
Sign Up to like & getrecommendations! Published in 2022 at "Anti-cancer drugs"
DOI: 10.1097/cad.0000000000001367
Abstract: Heterogeneity in the acquired genetic cause of osimertinib resistance leads to difficulties in understanding and addressing molecular mechanisms of resistance in clinical practice. Recent studies and clinical cases established that altered BRAF could drive osimertinib… read more here.
Keywords: d594n mutation; braf d594n; osimertinib plus; resistance ... See more keywords
Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of clinical pharmacy and therapeutics"
DOI: 10.1111/jcpt.13591
Abstract: WHAT IS KNOWN AND OBJECTIVE Although osimertinib achieved convincing efficacy for patients with EGFR T790M-positive non-small-cell lung cancer (NSCLC) as second-line treatment in the AURA3 clinical trials, patients developed drug resistance ultimately. Therefore, the present… read more here.
Keywords: t790m positive; plus anlotinib; study; safety ... See more keywords
Osimertinib plus Ramucirumab: The Best of Both Worlds?
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-4026
Abstract: Both osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation–positive non–small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation–positive patients. The accompanying article… read more here.
Keywords: plus ramucirumab; osimertinib plus; ramucirumab best; best worlds ... See more keywords
Osimertinib plus repotrectinib phase I trial in TKI-resistant non-small cell lung cancer (NSCLC) with EGFR mutations.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.8604
Abstract: 8604 Background: NSCLC patients with EGFR mutations develop resistance when treated with EGFR TKI. We previously reported that osimertinib combined with TPX-0005 (repotrectinib) ablated STAT3, paxillin, and YAP1 phosphorylation in a preclinical model. Osimertinib-induced Src… read more here.
Keywords: treatment; tpx 0005; part; osimertinib plus ... See more keywords